FINANCINGS

Adamis Pharmaceuticals Corp. entered definitive subscription agreements with investors for a registered direct offering for gross proceeds of about $11.1 million.

Ambrx Inc. closed a $45 million financing round.

Avrobio Inc. raised $25 million in a series A financing.

Azurrx Biopharma Inc. set terms for its IPO, hoping to raise $15 million from the sale of 2.14 million shares of common stock priced in the range of $6 and $8 each.

Bioniz Therapeutics Inc. closed a $13 million series A financing.

Cardiome Pharma Corp. closed its public offering for gross proceeds of $34.5 million.

Edge Therapeutics Inc. closed a $20 million dual-tranche term loan with Hercules Capital Inc.

Evoke Pharma Inc. entered definitive agreements with institutional investors for a registered direct offering to raise gross proceeds of about $10 million.

Heron Therapeutics Inc. said Tang Capital Partners LP agreed to lend the company up to $100 million. It will have a two-year term and bear interest of 8 percent per year.

Inotek Pharmaceuticals Corp. priced an underwritten public offering of $50 million of 5.75 percent convertible senior notes, maturing Aug. 1, 2021.

Steadymed Ltd. entered definitive agreements to sell shares of its common stock and warrants for gross proceeds of about $32 million in a two-tranche private placement.

DEALS

Adicet Bio Inc. has signed a five-year deal with Regeneron Pharmaceuticals Inc. to engineer immune cells with fully human CARs and TCRs directed to disease-specific cell surface antigens.

Amgen Inc. has partnered with Advaxis Inc. for its preclinical cancer immunotherapy.

Aeterna Zentaris Inc. signed an agreement for its lead cancer compound, Zoptrex (zoptarelin doxorubicin), for the initial indication of endometrial cancer, with Rafa Laboratories Ltd.

Altimmune Inc. was awarded a contract valued at up to $120.2 million over five years from the U.S. Biomedical Advanced Research and Development Authority to fund the clinical development of Nasoshield, its anthrax vaccine candidate.

Biogen Inc. and Amyris Inc. entered a funded partnership to explore the use of Amyris' microbe engineering technology to develop multiple host microorganisms as alternatives to mammalian cell lines for the production of therapeutic recombinant proteins.

Biolinerx Ltd. signed an agreement with Hadasit, the technology transfer company of Hadassah Medical Organization, to in-license a drug candidate to treat liver fibrosis.

Catalyst Biosciences Inc. is selling to virtual biotech Attenua Inc. certain oral neuronal nicotinic receptor assets that were under development by Targacept Inc. prior to its 2015 merger with Catalyst.

Glaxosmithkline plc and Google's parent company, Alphabet Inc., have established a joint venture to evaluate bioelectronics medicine to combat chronic conditions.

Jazz Pharmaceuticals plc licensed global rights to several early stage blood cancer candidates from Pfenex Inc. in a deal that also included an option on an exclusive license for PF690, a biosimilar of Baxalta Inc.'s acute lymphoblastic leukemia therapy.

Pfizer Inc. acquired Bamboo Therapeutics Inc., paying $150 million up front and committing to milestone payments of up to $495 million just months after investing $43 million for a 22 percent equity stake.

Sorrento Therapeutics Inc. is creating a joint venture with CHA Biotech Co. Ltd. to develop CAR-modified cellular therapies based on CBT's activated killer cell technology and five of Sorrento's CARs for all disease conditions, including oncology and infectious diseases.

Vortex Biosciences Inc. has licensed a series of four patents covering a cell electroporation technology from Harvard University.

. . . AND MORE

Foundation Medicine Inc.'s Foundationone pan-cancer comprehensive genomic profiling assay will be reviewed via the FDA's Expedited Access Pathway. In addition, it will be evaluated for reimbursement via the FDA/Centers for Medicare & Medicaid Services parallel review program.

Inspection issues and deficiencies at contract manufacturers for Adma Biologics Inc.'s primary immunodeficiency treatment, RI-002, drew an FDA complete response letter for the company's biologics license application.

Ipsen SA said the FDA approved Dysport (abobotulinumtoxinA) as an injection to treat pediatric lower limb spasticity in those 2 and older.

Merck & Co. Inc. said the European Commission approved Zepatier (elbasvir/grazoprevir) with or without ribavirin for the treatment of chronic hepatitis C virus genotype 1 or 4 infection in adults.

Shire plc gained fast track designation for SHP626 (volixibat) as an investigational treatment of adults who have nonalcoholic steatohepatitis with liver fibrosis.

Tokai Pharmaceuticals Inc. said it is reducing its workforce by about 60 percent, to a total of 10 full-time equivalent employees.